Compare Moderna, Inc. (MRNA) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Oxford Lane Capital Corp — how do they compare? Moderna, Inc. trades at $135.95 (market cap $56.02B), while Oxford Lane Capital Corp trades at $9.67 (market cap $942.56M). The key difference: Moderna, Inc. is far larger — about 59.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 24.96% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | OXLC | |
|---|---|---|
Market Cap | $56.02B | $942.56M |
Sector | Health | Financials |
52-Week High | $174.38 | $17.73 |
52-Week Low | $22.36 | $8.15 |
Enterprise Value | $52.17B | — |
Dividend Yield | — | 24.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
OXLC trades at $9.61, down 0.52% on the day, with a bullish technical signal supported by moving averages but mixed earnings performance. Recent quarters show significant misses versus expectations, including a large loss in Q1 2026, though the company maintains a steady dividend payout. Net income margin is exceptionally high at 100.85% for 2026, but this follows negative revenue, while 2025 showed positive net income of $48.46M. The P/B ratio of 0.91 suggests the stock trades below book value.
Outlook is cautious due to volatile earnings and high yield sustainability concerns, with analyst sentiment split evenly between buy and sell ratings. Key risks include earnings instability and reliance on financing cash flow, but the discount to book value and consistent dividends may appeal to income-focused investors amid bullish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
